<DOC>
	<DOCNO>NCT00878943</DOCNO>
	<brief_summary>In early study , sildenafil citrate administer patient PAH lead improvement pulmonary arterial pressure , cardiac output , quality life , parameter compare placebo . This protocol provide mechanism patient clinical deterioration PAH approve therapy access sildenafil prior market authorization India .</brief_summary>
	<brief_title>Open Label Access Study Of Sildenafil In Adult Patients With Pulmonary Arterial Hypertension Completing A1481244 Study</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Sildenafil Citrate</mesh_term>
	<criteria>Subject complete A1481244 study require Sildenafil ( Revatio TM ) 20 mg TID therapy . All woman childbearing potential must use adequate contraception throughout study four week completion study Pregnant lactate woman Participation study study participation Other severe acute chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Open label access</keyword>
	<keyword>sildenafil</keyword>
	<keyword>pulmonary arterial hypertension</keyword>
</DOC>